Evidence mapPaperPMID 25409370Full record

Observational studyThe New England journal of medicine2014

Glycemic control and excess mortality in type 1 diabetes.

Marcus Lind, Ann-Marie Svensson, Mikhail Kosiborod, Soffia Gudbjörnsdottir, Aldina Pivodic, Hans Wedel, Sofia Dahlqvist, Mark Clements, Annika Rosengren

2 registry-linked trialsAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in The New England journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 402 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
402citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03819790 phase4completedstarted 2018, after this paper: background citation

Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)

Ran2018Enrolled119Registered outcomes30Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsBasal insulin Basaglar/Lantus + gliclazide MR, Basal insulin glargine and lixisenatide, Metformin
Open the trial in the graph
NCT04730882 completednot on this mapstarted 2021, after this paper: background citation

Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults

TypeobservationalSponsorUniversity of VirginiaRan2021 to 2024Enrolled36ConditionsType 1 Diabetes, Hyperglycemia, PostprandialArmsMixed Meal
3 · Its place in the literature

Who cites it

402 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Real-World Glucometric Outcomes of the MiniMed 780G Advanced Hybrid Closed-Loop System in Users with Type 1 Diabetes in Spain.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  18. Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  19. Trajectory of Kidney Function in T1D over Time: A Scoping Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  20. Article

342 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Marcus LindFrom the Department of Medicine, NU-Hospital Organization, Uddevalla (M.L., S.D.), Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg (M.L., S.G., A.R.), Center of Registers in Region Västra Götaland (A.-M.S.), Statistiska Konsultgruppen (A.P.), Nordic School of Public Health (H.W.), and Sahlgrenska University Hospital (A.R.), Gothenburg - all in Sweden; Saint Luke's Mid America Heart Institute (M.K.), University of Missouri-Kansas City School of Medicine (M.K., M.C.), and Children's Mercy Hospital (M.C.), Kansas City, MO; and the University of Kansas School of Medicine, Kansas City, KS (M.C.).
Ann-Marie Svensson
Mikhail Kosiborod
Soffia Gudbjörnsdottir
Aldina Pivodic
Hans Wedel
Sofia Dahlqvist
Mark Clements
Annika Rosengren

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes.

methodsWe included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality.

resultsThe mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37).

conclusionsIn our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).

Indexed as

AdultCardiovascular DiseasesCase-Control StudiesDiabetes Mellitus, Type 1FemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMiddle AgedRegistriesRiskSwedenGlycated Hemoglobin

Identifiers

PMID25409370

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.